Supernus secures seven years of FDA orphan-drug exclusivity for ONAPGO, seeks second supplier approval by mid-2027

Supernus has secured seven years of FDA orphan-drug exclusivity for ONAPGO and is seeking approval of a second supplier by mid-2027.

Detected & updated continuously · Source: Nebula